3-amino-4-cyclopropyl-but-2-enoic acid ethyl ester | 851070-40-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-amino-4-cyclopropyl-but-2-enoic acid ethyl ester
• 英文别名: 3-Amino-4-cyclopropyl-but-2-enoic acid ethyl ester；ethyl 3-amino-4-cyclopropylbut-2-enoate
• CAS: 851070-40-1
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: IYJUWIHLKMYKIX-UHFFFAOYSA-N

物化性质

• 沸点：
  280.7±13.0 °C(Predicted)
• 密度：
  1.074±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  二(2,4,6-三氯苯基)苯基丙二酸酯 、 3-amino-4-cyclopropyl-but-2-enoic acid ethyl ester 在 sodium hydroxide 作用下， 以 neat (no solvent) 为溶剂， 反应 1.75h， 以9.8%的产率得到6-(cyclopropylmethyl)-4-hydroxy-3-phenylpyridin-2(1H)-one
  参考文献：
  名称：

  Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents

  摘要：

  Pyridone 1 was identified from a high-throughput cell-based phenotypic screen against Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis (MDR-TB) as a novel anti-TB agent and subsequently optimized series using cell-based Mtb assay. Preliminary structure activity relationship on the isobutyl group with higher cycloalkyl groups at 6-position of pyridone ring has enabled us to significant improvement of potency against Mtb. The lead compound 30j, a dimethylcyclohexyl group on the 6-position of the pyridone, displayed desirable in vitro potency against both drug sensitive and multi-drug resistant TB clinical isolates. In addition, 30j displayed favorable oral pharmacokinetic properties and demonstrated in vivo efficacy in mouse model. These results emphasize the importance of 4-hydroxy-2-pyridones as a new chemotype and further optimization of properties to treat MDR-TB. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.10.008
• 作为产物：
  描述：

  5-(1-Amino-2-cyclopropyl-ethylidene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 在 sodium 作用下， 以 乙醇 为溶剂， 反应 14.0h， 以77%的产率得到3-amino-4-cyclopropyl-but-2-enoic acid ethyl ester
  参考文献：
  名称：

  Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents

  摘要：

  这项发明涉及以下式的化合物 其中R 6 、R 7 和R 8 中的一个是 和X、Y 1 至Y 4 、R 1 至R 14 和n如描述中所定义的，并且所有的对映体和药用盐和/或酯。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防由PPARδ和/或PPARα激动剂调节的疾病。

  公开号：

  US20050096353A1

文献信息

• Phenyl derivatives, their manufacture and use as pharmaceutical agents
  申请人：Ackermann Jean

  公开号：US20050096337A1

  公开（公告）日：2005-05-05

  This invention relates to compounds of the formula wherein one of R 5 , R 6 and R 7 is and X 1 , X 2 , Y 1 to Y 4 , R 1 to R 13 and m and n are defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.

  本发明涉及式子中的化合物，其中R5、R6和R7中的一个为氢，X1、X2、Y1至Y4、R1至R13和m和n在说明书中有定义，并涉及其所有对映体和药学上可接受的盐和/或酯。本发明进一步涉及含有这些化合物的制药组合物，以及制备它们的过程和它们用于治疗和/或预防由PPARδ和/或PPARα激动剂调节的疾病的用途。
• Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents
  申请人：Ackermann Jean

  公开号：US20050096353A1

  公开（公告）日：2005-05-05

  This invention relates to compounds of the formula wherein one of R 6 , R 7 and R 8 is and X, Y 1 to Y 4 , R 1 to R 14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.

  这项发明涉及以下式的化合物 其中R 6 、R 7 和R 8 中的一个是 和X、Y 1 至Y 4 、R 1 至R 14 和n如描述中所定义的，并且所有的对映体和药用盐和/或酯。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防由PPARδ和/或PPARα激动剂调节的疾病。
• Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents
  作者：Pearly Shuyi Ng、Ujjini H. Manjunatha、Srinivasa P.S. Rao、Luis R. Camacho、Ngai Ling Ma、Maxime Herve、Christian G. Noble、Anne Goh、Stefan Peukert、Thierry T. Diagana、Paul W. Smith、Ravinder Reddy Kondreddi

  DOI：10.1016/j.ejmech.2015.10.008

  日期：2015.12

  Pyridone 1 was identified from a high-throughput cell-based phenotypic screen against Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis (MDR-TB) as a novel anti-TB agent and subsequently optimized series using cell-based Mtb assay. Preliminary structure activity relationship on the isobutyl group with higher cycloalkyl groups at 6-position of pyridone ring has enabled us to significant improvement of potency against Mtb. The lead compound 30j, a dimethylcyclohexyl group on the 6-position of the pyridone, displayed desirable in vitro potency against both drug sensitive and multi-drug resistant TB clinical isolates. In addition, 30j displayed favorable oral pharmacokinetic properties and demonstrated in vivo efficacy in mouse model. These results emphasize the importance of 4-hydroxy-2-pyridones as a new chemotype and further optimization of properties to treat MDR-TB. (C) 2015 Elsevier Masson SAS. All rights reserved.